Pharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C.
The pharmacokinetics of intraperitoneal infusion 5-fluorouracil and bolus administration mitomycin-C have been evaluated and permit one to determine the exposure advantage for this route of administration. as with other forms of regional chemotherapy, the limiting toxicity is locoregional. The therapeutic efficacy of this approach awaits the design and conduct of clinical trials.
D001202:Ascitic Fluid / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D007274:Injections, Intraperitoneal; D007700:Kinetics; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D010529:Peritoneal Cavity
D008937:Mitomycins; D016685:Mitomycin; D005472:Fluorouracil